Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AR Antagonist (BMS-641988)
AR Antagonist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AR Antagonist (BMS-641988) | DRUG | Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses |
Inclusion Criteria: * Advanced castration-resistant prostate carcinoma with progressive disease * At least 4 weeks must have elapsed from major surgery * Patient must be available for follow-up * Adequate liver and kidney function * Adequate blood values Exclusion Criteria: * Uncontrolled or sign...
Top 20 of 55 competitors
The AR Antagonist (BMS-641988) is an investigational small molecule developed by Bristol-Myers Squibb Company for prostate cancer. It was studied in a Phase 1 dose-escalation trial in patients with castration-resistant prostate cancer. It is not an approved therapy and remains an early-stage clinical candidate.
The AR Antagonist (BMS-641988) was studied for the treatment of prostate cancer, specifically castration-resistant prostate cancer. Its only recorded clinical trial enrolled men with that condition. The drug is investigational and has not been approved for any indication.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, developed the AR Antagonist (BMS-641988). The company sponsored the Phase 1 dose-escalation study of the compound in castration-resistant prostate cancer.
The AR Antagonist (BMS-641988) is in Phase 1 development. One Phase 1 dose-escalation trial has been completed, and no trials are currently active. The drug is investigational and has not received FDA approval.
The AR Antagonist (BMS-641988) was evaluated in one completed Phase 1 trial, NCT00326586, titled a Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer. The trial enrolled 54 men in the United States and has completed.
Yes, the AR Antagonist and BMS-641988 refer to the same compound. BMS-641988 is the Bristol-Myers Squibb development code for this investigational small molecule, which was studied in a Phase 1 trial in castration-resistant prostate cancer.